NPC1L1 and metabolic dysfunction-associated steatotic liver disease: Re‐analysis of this data set showed that NPC1L1‐expression levels in the livers of patients with steatosis and NASH were higher than those in normal controls (Supplemental Figure S8), suggesting that subjects with higher levels of NPC1L1 may be more prone to NAFLD.